Lack of follow-up in Helicobacter pylori eradication treatment: Results from the European registry on Helicobacter pylori management

doi:10.3748/wjg.v32.i7.113541

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 7

This Article

(57)

(47)

(1)

(0)

(1)

(1563)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. Feb 21, 2026; 32(7): 113541
Published online Feb 21, 2026. doi: 10.3748/wjg.v32.i7.113541

Table 3 Factors associated with non-retreatment of Helicobacter pylori after a therapeutic failure-univariate analysis, n (%)

Variables	Retreatment (n = 5954)	Non-retreatment
		Overall (n = 950)		Medical perspective (n = 393)		Patient perspective (n = 474)
		n (%)	P value	n (%)	P value	n (%)	P value
Sex
Male	2100 (35.3)	386 (40.6)	0.002	147 (37.4)	0.397	206 (43.5)	0.000
Female	3850 (64.7)	564 (59.4)		246 (62.6)		268 (56.5)
Age, years
18-70	5455 (91.6)	851 (89.5)	0.018	350 (89.1)	0.116	430 (90.7)	0.329
≥ 71	475 (7.9)	96 (10.1)		40 (10.9)		44 (9.3)
Ethnicity
Caucasian	5148 (86.6)	810 (85.3)	0.084	344 (87.6)	0.012	391 (82.5)	0.000
Afro-American	70 (1.2)	8 (0.8)		5 (1.3)		1 (0.2)
Asian	79 (1.3)	12 (1.3)		7 (1.8)		3 (0.6)
Others	405 (6.8)	63 (6.6)		34 (8.6)		25 (5.3)
Reclassified indication¹
Highly recommended	1075 (18.1)	182 (19.2)	0.413	80 (20.4)	0.252	87 (18.4)	0.871
Poorly recommended	4879 (81.9)	768 (80.8)		313 (79.6)		387 (81.6)
Number of previous eradication attempts			0.000		0.000		0.000
None	4381 (73.6)	561 (59.1)		194 (49.4)		320 (67.5)
One attempt	1054 (17.7)	181 (19.1)		82 (20.9)		82 (17.3)
Two attempts	334 (5.6)	105 (11.1)		61 (15.5)		26 (5.5)
Three attempts	115 (1.9)	63 (6.6)		39 (9.9)		21 (4.4)
Four attempts	42 (0.7)	27 (2.8)		12 (3.1)		10 (2.1)
Five attempts	28 (0.5)	13 (1.4)		5 (1.3)		5 (1.1)
Treatment compliance²	5647 (94.8)	739 (77.8)	0.000	303 (77.1)	0.000	358 (75.5)	0.000
At least one AE	1277 (21.4)	234 (24.6)	0.051	103 (26.2)	0.046	116 (24.5)	0.193
Severe AE³	137 (2.3)	44 (4.6)	0.000	24 (6.1)	0.000	18 (3.8)	0.041
Serious AE⁴	9 (0.2)	5 (0.5)	0.017	5 (1.3)	0.000	0	0.397
Interruption by AE	183 (3.1)	109 (11.5)	0.000	68 (17.3)	0.000	39 (8.2)	0.000

¹Highly recommended: Preneoplastic lesions, personal history of gastric cancer with surgical and/or endoscopic resection, 1^st degree relatives of patients with gastric cancer, mucosa-associated lymphoid tissue lymphoma, and gastric or duodenal ulcers. Poorly recommended: Functional and uninvestigated dyspepsia, vitamin B12 deficiency, treatment with nonsteroidal anti-inflammatory drugs or acetylsalicylic acid, prolonged treatment with proton pump inhibitors, iron deficiency anemia, idiopathic thrombocytopenic purpura.

²Compliance: > 90% drug intake.

³Severe adverse event: Refers to the intensity of the symptoms.

⁴Serious adverse event: Unexpected medical occurrence, such as life-threatening, risk of hospitalization, or malformations.

AE: Adverse event.

Full Size Table

Citation: Cantú-Germano E, Moreira L, Pérez-Aisa Á, Martínez-Domínguez SJ, Voynovan I, Bujanda L, Jonaitis L, Tepes B, Garre A, Lucendo AJ, Lerang F, Butler T, Mahmudov U, Huguet JM, Tejedor-Tejada J, Bogomolov P, Beales IL, Phull PS, Pabon-Carrasco M, Castro-Fernández M, Alekseenko S, Pavoni M, Zaytsev O, Bumane R, Denkovski M, Cajal MD, Tatiana I, Areia M, Keco-Huerga A, Babayeva G, Bermejo F, Simsek H, Buzás GM, Losurdo G, Bordin DS, Kupcinskas J, Smith SM, Gasbarrini A, Leja M, Marcos-Pinto R, Simsek C, Papp V, Rodríguez BJ, Mejide PP, Villarroya RP, Alonso MS, Cano-Català A, Megraud F, O’Morain C, Parra P, Nyssen OP, Gisbert JP. Lack of follow-up in Helicobacter pylori eradication treatment: Results from the European registry on Helicobacter pylori management. World J Gastroenterol 2026; 32(7): 113541
URL: https://www.wjgnet.com/1007-9327/full/v32/i7/113541.htm
DOI: https://dx.doi.org/10.3748/wjg.v32.i7.113541

Cantú-Germano E, Moreira L, Pérez-Aisa Á, Martínez-Domínguez SJ, Voynovan I, Bujanda L, Jonaitis L, Tepes B, Garre A, Lucendo AJ, Lerang F, Butler T, Mahmudov U, Huguet JM, Tejedor-Tejada J, Bogomolov P, Beales IL, Phull PS, Pabon-Carrasco M, Castro-Fernández M, Alekseenko S, Pavoni M, Zaytsev O, Bumane R, Denkovski M, Cajal MD, Tatiana I, Areia M, Keco-Huerga A, Babayeva G, Bermejo F, Simsek H, Buzás GM, Losurdo G, Bordin DS, Kupcinskas J, Smith SM, Gasbarrini A, Leja M, Marcos-Pinto R, Simsek C, Papp V, Rodríguez BJ, Mejide PP, Villarroya RP, Alonso MS, Cano-Català A, Megraud F, O’Morain C, Parra P, Nyssen OP, Gisbert JP. Lack of follow-up in Helicobacter pylori eradication treatment: Results from the European registry on Helicobacter pylori management. World J Gastroenterol 2026; 32(7): 113541 [PMID: 41694498 DOI: 10.3748/wjg.v32.i7.113541]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.